BAVIS_1170x120_1-20

Paul Hudson

Novartis and Amgen announce FDA approval of Aimovig

Novartis and Amgen announce FDA approval of Aimovig

Basel, SWITZERLAND – Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Aimovig (erenumab) for the preventive treatment of migraine in adults. Aimovig is a novel therapeutic approach as the first and only FDA-approved treatment specifically developed to prevent migraine by blocking the calcitonin gene-related peptide receptor (CGRP-R), which is believed to

Novartis realigns pharma division into two new units

Novartis realigns pharma division into two new units

BASEL, Switzerland — Making changes to its Pharmaceuticals Division, Novartis has created two business units that will report to the chief executive officer: Novartis Pharmaceuticals and Novartis Oncology. The new units will form the Innovative Medicines Division. Novartis said Tuesday that the new structure reflects the importance of oncology following the integration of oncology assets